Tags

Type your tag names separated by a space and hit enter

CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Ital J Gastroenterol. 1994 May; 26(4):169-73.IJ

Abstract

This study compared the sensitivity and specificity of CA 50 and CA 19-9 as serum tumour markers for pancreatic cancer. One hundred and seventy one subjects were evaluated: 50 healthy controls, 50 patients with pancreatic carcinoma and 71 patients with chronic pancreatitis. Eighty per cent of the pancreatic cancer patients had raised CA 19-9 serum levels and 82% had raised CA 50 serum levels. In the group of patients ith chronic pancreatitis, false positive tests occurred in 8.4% for CA 19-9 and 11.3% for CA 50. For both markers the serum level showed a severe elevation in the advanced stage of cancer disease. Despite the good sensitivity and specificity of CA 50 as a serum tumour marker for pancreatic carcinoma, no major advantage was found compared to CA 19-9. Moreover, if the CA 50 cut-off, level is raised to 85 U/ml to exclude overlap with chronic pancreatitis, sensitivity falls sharply to 46% compared with 72% for CA 19-9 when a 100 U/ml cut-off level is used.

Authors+Show Affiliations

Istituto di Semeiotica Chirurgica, Università di Padova, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7949259

Citation

Pasquali, C, et al. "CA 50 Compared With CA 19-9 as a Serum Tumour Marker for Pancreatic Carcinoma." The Italian Journal of Gastroenterology, vol. 26, no. 4, 1994, pp. 169-73.
Pasquali C, Sperti C, D'Andrea AA, et al. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma. Ital J Gastroenterol. 1994;26(4):169-73.
Pasquali, C., Sperti, C., D'Andrea, A. A., Costantino, V., Filipponi, C., & Pedrazzoli, S. (1994). CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma. The Italian Journal of Gastroenterology, 26(4), 169-73.
Pasquali C, et al. CA 50 Compared With CA 19-9 as a Serum Tumour Marker for Pancreatic Carcinoma. Ital J Gastroenterol. 1994;26(4):169-73. PubMed PMID: 7949259.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma. AU - Pasquali,C, AU - Sperti,C, AU - D'Andrea,A A, AU - Costantino,V, AU - Filipponi,C, AU - Pedrazzoli,S, PY - 1994/5/1/pubmed PY - 1994/5/1/medline PY - 1994/5/1/entrez SP - 169 EP - 73 JF - The Italian journal of gastroenterology JO - Ital J Gastroenterol VL - 26 IS - 4 N2 - This study compared the sensitivity and specificity of CA 50 and CA 19-9 as serum tumour markers for pancreatic cancer. One hundred and seventy one subjects were evaluated: 50 healthy controls, 50 patients with pancreatic carcinoma and 71 patients with chronic pancreatitis. Eighty per cent of the pancreatic cancer patients had raised CA 19-9 serum levels and 82% had raised CA 50 serum levels. In the group of patients ith chronic pancreatitis, false positive tests occurred in 8.4% for CA 19-9 and 11.3% for CA 50. For both markers the serum level showed a severe elevation in the advanced stage of cancer disease. Despite the good sensitivity and specificity of CA 50 as a serum tumour marker for pancreatic carcinoma, no major advantage was found compared to CA 19-9. Moreover, if the CA 50 cut-off, level is raised to 85 U/ml to exclude overlap with chronic pancreatitis, sensitivity falls sharply to 46% compared with 72% for CA 19-9 when a 100 U/ml cut-off level is used. SN - 0392-0623 UR - https://www.unboundmedicine.com/medline/citation/7949259/CA_50_compared_with_CA_19_9_as_a_serum_tumour_marker_for_pancreatic_carcinoma_ L2 - https://medlineplus.gov/pancreatitis.html DB - PRIME DP - Unbound Medicine ER -